Last Updated: August 3, 2026

Details for Patent: 11,413,351

Name: Drug Patent Intelligence for US Patent 11413351
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,413,351 protect, and when does it expire?

Patent 11,413,351 protects YUVIWEL and is included in one NDA.

This patent has twenty-three patent family members in sixteen countries.

Summary for Patent: 11,413,351

Title:	CNP prodrugs with carrier attachment at the ring moiety
Abstract:	The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.
Inventor(s):	Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
Assignee:	Ascendis Pharma Endocrinology Division AS
Application Number:	US16/067,095
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 11,413,351

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ascendis	YUVIWEL	navepegritide	POWDER;SUBCUTANEOUS	219164-001	Feb 27, 2026		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y			⤷ Start Trial
Ascendis	YUVIWEL	navepegritide	POWDER;SUBCUTANEOUS	219164-002	Feb 27, 2026		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y			⤷ Start Trial
Ascendis	YUVIWEL	navepegritide	POWDER;SUBCUTANEOUS	219164-003	Feb 27, 2026		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,413,351

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017205688	⤷ Start Trial
Australia	2021277638	⤷ Start Trial
Australia	2023210599	⤷ Start Trial
Australia	2024278289	⤷ Start Trial
Canada	3007979	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.